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Primary hyperparathyroidism (PHPT) is a rare endocrine disease in the pediatric population. Sporadic
parathyroid adenomas remain the most common cause of pediatric PHPT. Parathyroid carcinoma (PC)
is an extremely rare cause of pediatric PHPT.We report a 16-year-old boy presenting with a nonhealing
fragility fracture of the right leg along with florid features of rickets. Examination revealed a neckmass,
mimicking a goiter. Biochemical findings were consistent with PHPT. Imaging was suggestive of a right
inferior parathyroid mass infiltrating the right lobe of thyroid. The patient underwent en bloc surgical
excision of the parathyroid mass along with the right lobe of thyroid. Histopathology was suggestive of a
PC. He achieved biochemical remission with normalization of serum calcium and parathyroid hormone
levels. At follow-up, there was no biochemical or imaging evidence of recurrence or metastasis. Genetic
analysis revealed heterozygous germline deletion of CDC73. An extensive literature search on PC was
conducted, with an emphasis on the pediatric population. Thirteen cases of pediatric PCwere identified.
Themedian age of presentationwas 13 years; therewas no sex predilection. All caseswere symptomatic;
31% had a visible neck mass. The median serum calcium and intact parathyroid hormone levels were
14.3 mg/dL and 2000 pg/mL, respectively. All patients underwent surgical excision, with 27% showing
metastatic relapse. Our findings indicate that the preoperative features that could point toward a
diagnosis of PC in a child with PHPT are a tumor size of .3 cm, thyroid infiltration on imaging, and
severe hypercalcemia at presentation.
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Primary hyperparathyroidism (PHPT) is an uncommon endocrine disease in the pediatric
population. The prevalence of pediatric PHPT is two to three cases per 100,000 [1]. Sporadic
parathyroid adenomas remain the most common cause of PHPT (up to 80%) in this age group.
Other causes include various syndromes, such asmultiple endocrine neoplasia (MEN)1,MEN2A,
hyperparathyroidism-jaw tumor (HPT-JT) syndrome and familial isolated hyperparathyroidism,
Abbreviations: HPT-JT, hyperparathyroidism-jaw tumor; iPTH, intact parathyroid hormone; MEN, multiple endocrine neoplasia;
PC, parathyroid carcinoma; PHPT, primary hyperparathyroidism.
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which includes cases with GCM2 germline mutation. Parathyroid carcinoma (PC) as a
cause of pediatric PHPT is extremely rare, and only a handful of published case reports are
available in the literature [2–13]. The two largest case series of pediatric PHPT to date (with
55 and 52 patients, respectively) did not report a single case of pediatric parathyroid
carcinoma [14, 15]. In two systematic reviews on PHPT, parathyroid carcinoma contrib-
utes ,1% of the cases, almost all being adult cases [16, 17]. In this context, we report
parathyroid carcinoma in a boy who presented with a nonhealing fragility fracture, visible
neck swelling, and rachitic features. On reviewing the literature, in retrospect, wewere able
to pin-point some clinical, biochemical, and radiological features that could have predicted
the presence of PC in the index case.
1. Case Presentation
A 16-year-old boy presented to our institution with shortening and deformity (inwardly rotated)
involving the right leg. Background history revealed that he had sustained a fragility fracture of
right leg (tibia and fibula) 2 months back while climbing down from a vehicle. The injury was
managed with a cast for 6 weeks. However, the fracture did not heal and led to the present
deformity. On physical examination, his right leg was shortened and internally rotated (Fig. 1a).
Tenderness and crepitus were present at the site of fracture. The patient also had a 3 3 4 cm,
predominantly right-sided neck swelling. The swelling was firm and nontender and moved with
deglutition (Fig. 1b). The patient was short for his age (height SDS 26.3) and was prepubertal
(Tanner Stage A-P1G1). Other important clinical findings included an immature face, acro-
osteolysis, kyphosis, pectus carinatum, and florid rachitic features (rachitic rosary; Harrison
sulcus; and broad, tender ends of long bones) (Fig. 1c). Clinically, there was no evidence of jaw
tumor (as seen in HPT-JT syndrome). A history of similar complaints in other family members
was lacking. The patient’s initial biochemistry was as follows: serum-corrected calcium,
15.61 mg/dL (range, 8.8 to 10.2 mg/dL); serum phosphate, 2.88 mg/dL (range, 3.5 to 4.9 mg/dL);
alkaline phosphatase, 2780 IU/L (range, 52 to 171 IU/L); intact parathyroid hormone (iPTH),
2028 pg/mL (range, 15 to 65 pg/mL); 25(OH) vitamin D, 5.93 ng/mL (target range,.20 ng/mL);
serum creatinine, 0.7 mg/dL (range, 0.4 to 1.0 mg/dL); and normal thyroid function. Radiograph
showed classical findings of PHPT (diffuse radiolucency, cortical thinning, intracortical tun-
neling, lytic lesions suggestive of brown tumors, salt and pepper appearance of skull). In addition,
there was subperiosteal resorption of the phalanges, cupping and fraying of metaphysis, wid-
ening of the growth plate (Fig. 2a), bilateral coxa vara (Fig. 2b), and fracture of right tibia and
fibula (Fig. 2c). Ultrasound of the neck revealed amultilobular, hypervascular, hypo-echoic mass
posterior to and infiltrating into the right lobe of the thyroid.Ultrasound of the abdomen revealed
bilateral renal calculi, staghorn calculus in right renal pelvis, and pancreatic calcifications. CT
scan showed a 3.6 3 2.5 3 2.7 cm homogenously hypodense mass infiltrating postero-inferiorly
into the right lobe of the thyroid and entering the tracheo-esophageal groove (Fig. 2d). 99mTc-
methoxyisobutylisonitrile/single-photon emission CT scintigraphy confirmed this lesion to be a
parathyroid mass. No jaw tumor was seen on CT in the mandible or maxilla.
Hypercalcemia was managed with saline diuresis and subcutaneous calcitonin. Sub-
sequently, the patient underwent open surgery under general anesthesia. The right inferior
parathyroidmass was identified, which was seen infiltrating the right lobe of the thyroid. The
mass along with the right lobe of the thyroid was removed en bloc. The rest of the three
parathyroid glands were explored and were intraoperatively identified as being normal and
were left in situ. No enlarged lymph node or tracheal, esophageal, or recurrent laryngeal
nerve infiltration were seen. Postoperatively the patient developed hungry bone syndrome on
day 2 and was managed with oral and intravenous calcium, oral calcitriol, and cholecalciferol
supplementations. Postoperatively, his iPTH and calcium were reduced to 16.36 pg/mL and
8.9 mg/dL, respectively. Histopathology showed a nodular tumor tissue measuring 3 3 3 3
2.5 cm and weighing 10 g. The tumor tissue showed nests of moderately pleomorphic tumor
cells with intervening fibrous septae. There was microscopic evidence of thyroid, vascular,
and neural invasion. The Ki-67 index was documented to be 15% (Fig. 3a–d). The patient is
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being regularly followed at 3-month intervals, and at 1.5 years of follow-up, he is bio-
chemically disease free. 18F-fluoro-2-deoxy-2-D-glucose positron emission tomography/CT
performed at 3, 6, and 18 months of follow-up did not show FDG-avid loco-regional or
metastatic disease. Radiologically, his rachitic features have markedly improved.
Genetic analysis for MEN 1 was negative. On Sanger sequence analysis of HRPT2
(CDC73), no pathogenic variant was detected. However, multiplex ligand-dependent probe
Figure 1. Clinical photograph of the patient showing (a) shortened and internally rotated
right leg, (b) prominent right-sided neck swelling, and (c) broadened right wrist suggestive of
rickets.
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amplification (MLPA®, SALSA MLPA P466 CDC73 probemix; MRC-Holland, Amsterdam,
Netherlands) analysis revealed a heterozygous germline deletion ofCDC73, with the deletion
extending into the flanking regions (performed at Oxford Medical Genetics Laboratories,
Oxford, United Kingdom). Immunohistochemistry for parafibromin (BSB-50, Bio SB, 1:200,
Santa Barbara, CA) was performed on the tumor tissue, adjacent normal parathyroid tissue,
positive (colonic mucosa) and negative (hepatocytes) controls. The tumor tissue showed
sparse nuclear positivity for parafibromin, whereas the normal parathyroid tissue showed
diffuse positivity (Fig. 4a–d). We will regularly follow the patient and will be vigilant on the
emergence of clinical features suggestive of HPT-JT syndrome.
2. Review of the Literature
We conducted an extensive MEDLINE, PubMed, and Embase search using the terms
“parathyroid cancer,” “parathyroid carcinoma,” “parathyroid malignancy,” “pediatric para-
thyroid carcinoma,” “pediatric parathyroid cancer,” “pediatric parathyroid malignancy,”
“parathyroid carcinoma in a child,” “parathyroid cancer in a child,” and “parathyroid ma-
lignancy in a child.” In total, we could find only 13 cases (n 5 7 female, n 5 6 male) in the
English language, highlighting the paucity of this diagnosis in the pediatric population. Our
Figure 2. Radiograph of the patient showing (a) subperiosteal resorption of the phalanges,
widening of the growth plates of the right wrist, cupping and fraying of the distal ends of
right radius and ulna (green arrow); (b) bilateral coxa vara; and (c) thinning of the cortices of
leg bones, fracture of the right tibia and ulna, and well-defined lytic lesion involving the
proximal part of left tibia. (d) CT of the neck (axial image) showing a 3.6 3 2.5 3 2.7 cm
homogenously hypodense mass (black arrow) infiltrating postero-inferiorly into the right lobe
of the thyroid (orange arrow).
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index case adds value to this small number of existing cases (Table 1). Among these cases, the
median age at presentation was 13 years (range, 8 to 16 years). A family history of PHPT was
present in three cases, and a proved genetic etiology ofmutation inCDC73was present only in
case 13. Presenting complaints were reported in 13 cases, and all these cases were symp-
tomatic in diverse ways. A neck mass was visible in four cases (31%). The median total serum
calcium at diagnosis (reported in 12 cases) was 14.3mg/dL (range, 12 to 20.7mg/dL). Although
PTH was reported in 12 cases, the corresponding value in case 4 was in Eq/mL (radioim-
munoassay) and is not considered in this analysis. Themedian iPTH in the remaining 11 cases
was 2000 pg/mL (range, 190 to 8368 pg/mL). In seven of the cases, the carcinomawas localized
to inferior glands, and only one case was ectopic. Surgical records of only 12 patients are
available; among these, six patients underwent simple excision, of whom one case had a
follow-up hemithyroidectomy. Out of the six cases that underwent en bloc resection, five
received it up front, and one case received it after simple excision. Follow-up has been reported
in only 11 cases, of whom three cases (27%) had documented biochemical and image proven
metastatic relapse. Our case had several unique findings, including parathyroid mass dis-
guised as a goiter, severe hypercalcemia (.15 mg/dL), severe growth stunting, clinical fea-
tures of rickets, pancreatic calcifications, and staghorn renal pelvis calculus. In retrospect,
features such as size .3 cm, the presence of thyroid infiltration on ultrasonography, and
severe hypercalcemia could have suggested a high preoperative likelihood of parathyroid
cancer in this patient. Postoperatively, the presence of thyroid, neural, and vascular invasion
and a high Ki-67 index proved the case as parathyroid carcinoma. Immunohistochemistry for
Figure 3. (a) Photomicrograph showing parathyroid tumor tissue (black arrowheads)
infiltrating the thyroid parenchyma causing follicular destruction (red arrow; hematoxylin
and eosin; magnification 3100). (b) The tumor is seen causing vascular invasion (black
arrow; hematoxylin and eosin; magnification 3100) and (c) perineural invasion (black arrow;
hematoxylin and eosin; magnification 3200). (d) Ki-67 labeling index of the tumor tissue is
15% (magnification 3400).
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parafibromin (the protein encoded by HRPT2) showed sparse nuclear positivity; genetic
analysis revealed a heterozygous germline deletion of CDC73 extending to the flanking re-
gions. Such deletions have been shown to be pathogenic in the development of parathyroid
carcinomas [18].
3. Discussion
The index case depicts a unique clinical scenario wherein a child had presented with a
nonhealing fragility fracture and a visible neck mass. Although the biochemical diagnosis of
PHPT was straightforward, the etiological diagnosis of an underlying PC was not certain
prior to surgery. The pretest probability of it being a benign parathyroid adenoma was high.
However, soft pointers that suggested a diagnosis of parathyroid malignancy were a visible
neck mass (which was confirmed on imaging as being parathyroid in origin), surrounding
thyroid infiltration, and very high serum calcium levels. Thyroid infiltration was confirmed
intraoperatively, and the final diagnosis was clinched on histopathological examination.
Due to the lack of sufficient data on the entity of pediatric PC, the subsequent evidence on
parathyroid cancer is mostly derived from adult case series and reviews. References to
pediatric data are made wherever substantial evidence exists.
A. Prevalence
PHPT is an uncommon endocrine disease in the pediatric population, with a prevalence of two
to three cases per 100,000 [1]. Causes in this age group include sporadic adenomas (up to 80%)
Figure 4. Parafibromin immunohistochemistry (magnification 3400) showing (a) diffuse
positivity in normal parathyroid tissue as compared with (b) sparse nuclear positivity in
index parathyroid carcinoma. Representative images of (c) positive control (colonic mucosa)
and (d) negative control (hepatocytes).
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and familial syndromes like MEN 1 and MEN 2A, HPT-JT syndrome, and familial isolated
hyperparathyroidism. PC as an etiology of pediatric PHPT is rare, and no data on prevalence
or sex predilection are available in the pediatric population.
B. Pathogenesis
The pathogenesis of PC remains unknown. In adults, there have been associations with
irradiation [19], end-stage renal disease [20], and previous hyperplastic or adenomatous
parathyroid [21]. However, Schantz and Castleman [2] reviewed 70 cases and found no
evidence formalignant transformation of previously pathologic parathyroid tissue. According
to the Swedish Family Cancer Database, a previous diagnosis of thyroid cancer can be
considered amajor risk predictor formalignant parathyroid disease [22]. Germlinemutations
in HRPT2 gene (located on 1q21-q32), also known as CDC73, have been found in both
syndromic (HPT-JT syndrome) and sporadic (20% to 40%) parathyroid carcinomas [23].
Shattuck et al. [24] demonstrated that 10 of 15 (67%) apparently sporadic parathyroid
carcinomas hadHRPT2mutations, three of which had germlinemutations. Cardoso et al. [23]
summarized 66 cases of sporadic parathyroid carcinomas with CDC73 mutations. Three of
these cases had gross deletions, like our index case, whereas the majority of the others were
either truncatingmutations ormutations affecting only the start codon. There was no obvious
genotype–phenotype correlation. Accordingly, genetic testing for CDC73 is recommended in
every patient with PC. PC has also been described in the context of MEN 1 and MEN 2
syndromes and germline GCM2 mutations [25].
C. Presentation
PHPT in the pediatric population is almost always symptomatic irrespective of the un-
derlying cause [1]. Renal and bone manifestations are usually present at the time of di-
agnosis. There is no differentiating clinical feature or distinct severity of symptom/sign for PC
vs benign PHPT in this age group. Still, the presence of a palpable neck mass, a jaw tumor,
and a family history of HPT-JT syndrome have been postulated as risk factors for PC.
Atypical presentation in the form of nonfunctioning parathyroid carcinoma with normo-
calcemia has also been described [26, 27] but not in a child. PHPT is also known to present
with rachitic features in children; however, a similar presentation is yet to be reported in PC
[28, 29]. This has been ascribed to both nutritional vitamin D deficiency (due to anorexia,
nausea, and vomiting) and renal phosphate wasting. The index case also had florid ra-
chitic features at presentation, with both vitamin D deficiency and PHPT likely being the
contributing factors.
D. Diagnosis
The usual biochemical tests (serum and urinary calcium, phosphate, alkaline phosphatase,
vitamin D, iPTH, bone turnover markers) used for the diagnosis of PHPT are not robust
enough to discriminate between adenoma and carcinoma. Nevertheless, there have been
efforts to assess the preoperative risk of carcinoma in patients with PHPT using serum
calcium, human chorionic gonadotrophin, adenoma size, ultrasonographic characteristics,
and PTH assay ratio. Preoperative corrected calcium levels .3.0 mmol/L (.12.02 mg/dL)
were reported in 85.3% of patients with PC in one study [30]. In an observational study, both
urinary and serum human chorionic gonadotrophin (hyperglycosylated/malignant isoform
only) were found to be significantly elevated in subjects with PC compared with subjects with
benign PHPT [31]. Regarding the size, parathyroid carcinomas were found to be .3.0 cm in
80% of patients in one study [30] and 76.6% of patients in another report [32]. Consequently,
Schulte and Talat [33] proposed the “,31,3” rule for exclusion of parathyroid cancer, with a
positive predictive value of 99.8% in real-life populations. In a retrospective study of 16
parathyroid carcinomas, the presence of irregular margins, inhomogeneous echogenicity,
and a depth/width ratio $1 were found to be predictive of carcinoma [34]. In another study,
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the presence of infiltration and calcification predicted PC, with a positive predictive value of
100% [35]. Despite this evidence, there are no concrete recommendations to advocate the use
of ultrasonography or that of other imaging modalities (CT, 11C-methionine-PET, 99mTc-
MIBI SPECT) in patients with PC. We prefer a cervico-thoracic CT to gauge the local in-
vasiveness and extent of the lesion. Three studies have explored the differences in the
measurement of PTH using second- and third-generation assays [36–38]. These authors have
concluded that the PTH ratio (third-generation to second-generation assay) of.1.0 has a high
positive predictive value for a preoperative diagnosis of PC.
E. Treatment
As in adults, surgery is the most effective and possibly curative therapy for pediatric patients
with PC. The choice of surgical procedure is usually guided by the preoperative suspicion,
local extent of involvement, and intraoperative findings. Parathyroid adenomas are usually
locally excised. However, the latter is associated with an increased risk of positive surgical
margins along with single or multiple repeat surgeries in patients with parathyroid carci-
nomas [30]. For PC, en bloc excision of ipsilateral thyroid lobe and isthmus with central-
cervical lymph node compartments is recommended [33]. Some researchers prefer resection
of the involved recurrent laryngeal nerve if the tumor cannot be dissected from the nerve
completely [39]. En bloc/radical excision has been shown to be independently associated with
decreased PC recurrence [40]. In spite of this knowledge, most patients undergo simple
excision, which reflects the diagnostic challenges prior to initial surgery. If a frozen section
shows positive resection margins, a parallel intraoperative assessment of PTH and calcium
levels can identify persistent or residual disease. Persistent disease should be located and,
when possible, cleared surgically followed by adjuvant radiotherapy. In patients without
PTH excess, positive resection margins still predict a high risk of local recurrence, and such
individuals need close follow-up every 3 to 6 months for 5 to 10 years [33].
F. Histopathology
The criterion of parathyroid malignancy was laid down by Schantz and Castleman [2]. This
included existence of fibrous bands resulting in a lobular architecture, nuclear atypia
(macronucleoli), and mitotic figures. These features are quite inconsistent; thus, histopa-
thology is frequently questioned and challenged [41]. A definitive diagnosis of malignancy is
restricted to tumors displaying evidence of vascular invasion (in the capsule or adjacent
tissue), capsular invasion with growth into adjacent tissue, or metastasis [42]. A close
histological differential is atypical parathyroid adenoma, but the latter lacks vascular in-
vasion, metastases, or increased mitotic activity. A proliferation index (the Ki-67 index),
evaluated by the MIB1 antibody, higher than 5% is associated with a higher risk of ma-
lignancy and recurrence [43]. Immuno-histochemical staining for protein gene product 9.5
and parafibromin (encoded by CDC73) has been used to confirm the diagnosis because
carcinomas (with CDC73 mutations) are negative for these proteins [44].
G. Prognosis
Recurrence in parathyroid carcinoma is fairly common due to the propensity of loco-regional
spread or distant vascular dissemination. Recurrence has been reported in 51.6% patients in
the largest series [30]. Metastasis to lung (variably 40% to 80%), cervical nodes (up to 30%),
bones (up to 11%), and mediastinum occurs, but late in the course of the disease [30, 45]. The
mortality rate due to parathyroid cancer has been described to be 30% to 50% [30, 32].
In summary, due to the rarity of pediatric parathyroid carcinoma, the diagnosis of this
endocrine neoplasm remains a challenge. Recurrent elevation of iPTH after adenoma ex-
cision, histology (both gross and microscopic), surgeon’s notes (local invasion), and pre-
operative evidence (severe hypercalcemia, lesion size.3 cm, ultrasound characteristics) can
2232 | Journal of the Endocrine Society | doi: 10.1210/js.2019-00081
point toward the diagnosis. High suspicion allows for timely en bloc resection and a
favorable outcome.
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